title: Autologous tumor-specific cytotoxic T-lymphocytes in a child with neuroblastoma.
abstract: Activation of peripheral blood lymphocytes from a neuroblastoma patient by co-cultivation with autologous neuroblastoma cells in a mixed lymphocyte-tumor cell culture (A-MLTC) resulted in the generation of cytotoxic activity against the autologous neuroblastoma cell line HNB-MS. A-MLTC was set up in the presence of recombinant human interleukin-2 (IL-2). HNB-MS stimulator was treated with recombinant human interferon-gamma (IFN-gamma) prior to A-MLTC. CTL generated in short-term culture effectively lysed HNB-MS, while they had no effect on an Epstein-Barr virus transformed autologous B-cell line EB-MS. Moreover, CTL lysed 3 different allogeneic neuroblastoma cell lines, but not a rhabdomyosarcoma cell line RBB. Recombinant human tumor necrosis factor-alpha (TNF-alpha) and interleukin-4 (IL-4) enhanced and suppressed CTL generation, respectively, when added to the A-MLTC from the beginning of culture. CD3+ CD4- CD8+ T cells were the major anti-tumor effectors. Furthermore, 111indium-labeled CTL clearly accumulated in metastatic sites. These results indicate that CTL can be used for adoptive immunotherapy in neuroblastoma.
authors.affiliation: Department of Pediatrics, Mie University School of Medicine, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Azuma
authors.forename: M
authors.initials: M
authors.lastname: Hanada
authors.forename: S I
authors.initials: SI
authors.lastname: Masuda
authors.forename: Y
authors.initials: Y
authors.lastname: Komada
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
mesh_terms: D000008:Abdominal Neoplasms / Q000276:immunology* / Q000473:pathology; D000293:Adolescent; D002461:Cell Line, Transformed; D005260:Female; D006801:Humans; D009447:Neuroblastoma / Q000276:immunology* / Q000473:pathology; D010641:Phenotype; D015375:Receptors, Interleukin-2 / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D015375:Receptors, Interleukin-2